Global Thrombocytopenia-Absent Radius (TAR) Syndrome Market, By Treatment (Surgery, Intrauterine Platelet Transfusion, Genetic Counseling, Occupational Therapy, Physiotherapy, Others), Diagnosis (Blood Tests, Genetic Testing, ultrasonography, X-Ray, Others), Age of Onset (Neonatal, Antenatal), Dosage (Injection, Tablets, Others), Route of Administration (Oral, Intravenous, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.
Thrombocytopenia-Absent Radius (TAR) Syndrome Market Analysis and Size
Thrombocytopenia-absent radius (TAR) syndrome is a type of rare disorder that is present at birth. Around 90 percent of affected individuals develop symptoms associated with low levels of the platelets in the blood during the first year of life. The incidence of TAR syndrome is projected at 1:200,000-1:100,000. The disorder was originally described in siblings in the 1950s. More than 100 cases have since been recorded.
Data Bridge Market Research analyses a growth rate in the thrombocytopenia-absent radius (TAR) syndrome market in the forecast period 2023-2030. The expected CAGR of thrombocytopenia-absent radius (TAR) syndrome market is tend to be around 13 % in the mentioned forecast period. The market was valued at USD 0.94 billion in 2022, and it would grow up to USD 2.5 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Thrombocytopenia-Absent Radius (TAR) Syndrome Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Surgery, Intrauterine Platelet Transfusion, Genetic Counseling, Occupational Therapy, Physiotherapy, Others), Diagnosis (Blood Tests, Genetic Testing, ultrasonography, X-Ray, Others), Age of Onset (Neonatal, Antenatal), Dosage (Injection, Tablets, Others), Route of Administration (Oral, Intravenous, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Abbott, Merck & Co., Inc. (U.S.), AstraZeneca (U.K.), Abbott (U.S.), Biomerieux (France), Bio-Rad Laboratories, Inc. (U.S.), BioMarin (U.S.), Quotient Suisse SA (Switzerland), BAG Health Care GmbH (Germany), DiaSorin S.p.A (Italy), Danaher, Thermo Fisher Scientific Inc. (U.S.), Siemens Healthcare GmbH (Germany), Hologic, Inc. (U.S.), Dynatronics Corporation (U.S.), and Ito Co., Ltd (Japan)
|
|
Market Opportunities
|
|
Market Definition
The thrombocytopenia-absent radius (TAR) syndrome is known by the lack of blood cells which is involved in clotting and the absence of a bone called the radius in each forearm. This platelet shortage generally develops in childhood and progressively improves. Platelet counts can return to normal in many of the circumstances. Extreme bleeding in the brain and other organs can be life-threatening, particularly in the first year of life. Some affected children who survive this period and do not suffer from brain haemorrhages have a normal life expectancy and intellectual development.
Thrombocytopenia-Absent Radius (TAR) Syndrome Market Dynamics
Drivers
- Increasing Diagnostic Procedures
In many cases, the diagnosis of TAR syndrome is made at birth based upon a detailed clinical examination, identification of characteristic physical findings, and numerous specialized tests. Such testing are used to confirm the presence of thrombocytopenia, anemia, or other hematologic abnormalities as well as a radiograph of the forearm and renal ultrasonography of the kidneys. Cardiac evaluation may also be advised to detect any kind of heart abnormalities related to the disorder. Such kind of evaluation may include a clinical examination, during which heart and lung sounds are evaluated through use of a stethoscope, and multiple specialized tests that enable doctors to access the structure and function of the heart. Thus, it boost the market growth.
Opportunities
- Increasing Treatment Methods
The wide treatments for thrombocytopenia-absent radius (TAR) syndrome are being researched and developed recently. Several physicians may recommend preventive measures to help the affected infants and children to avoid infection, stress, or other factors that may precipitate thrombocytopenia. In addition to this, specialists specify that cow’s milk should be avoided, since its introduction may precipitate thrombocytopenic, eosinophilic, or “leukemoid” episodes. In individuals suffering from TAR syndrome, numerous orthopedic techniques may also be recommended, such as corrective braces, splints, and/or certain surgical measures. Treatment with specific medications, surgical intervention, or other measures may be necessary for affected individuals with congenital heart defects. Thus, all these treatment options enhance the market growth.
Restraints/Challenges
- High Cost of Treatment
The huge cost associated with the treatment processes involving surgeries and certain therapies cost quite high; thus, this increasing cost hinders the market growth.
This thrombocytopenia-absent radius (TAR) syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the thrombocytopenia-absent radius (TAR) syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Thrombocytopenia-Absent Radius (TAR) Syndrome Market Scope
The thrombocytopenia-absent radius (TAR) syndrome market is segmented on the basis of treatment, diagnosis, age of onset, dosage, route of administration, end-users and distribution channel . The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Surgery
- Intrauterine Platelet Transfusion
- Genetic Counseling
- Occupational Therapy
- Physiotherapy
- Others
Diagnosis
- Blood Tests
- Genetic Testing
- Ultrasonography
- X-Ray
- Others
Age of Onset
- Neonatal
- Antenatal
Dosage
- Injection
- Tablets
- Others
Route of Administration
- Oral
- Intravenous
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Thrombocytopenia-Absent Radius (TAR) Syndrome Regional Analysis/Insights
The thrombocytopenia-absent radius (TAR) syndrome market is analyzed and market size insights and trends are provided by treatment, diagnosis, age of onset, dosage, route of administration, end-users and distribution channel as referenced above.
The major countries covered in the thrombocytopenia-absent radius (TAR) syndrome market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is dominating the market in the forecast period because of the huge presence of major market players, high disposable income and well-developed healthcare infrastructure in this region.
Asia-Pacific is considered to grow over the coming years because of the growing patient pool, increasing investment in the healthcare sector and rising government support.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Thrombocytopenia-Absent Radius (TAR) Syndrome Share Analysis
The thrombocytopenia-absent radius (TAR) syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to thrombocytopenia-absent radius (TAR) syndrome market
Key players operating in the thrombocytopenia-absent radius (TAR) syndrome market include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Abbott, Merck & Co., Inc. (U.S.)
- AstraZeneca (U.K.)
- Abbott(U.S.)
- Biomerieux (France)
- Bio-Rad Laboratories, Inc. (U.S.)
- BioMarin (U.S.)
- Quotient Suisse SA (Switzerland)
- BAG Health Care GmbH (Germany
- DiaSorin S.p.A (Italy)
- Thermo Fisher Scientific Inc. (U.S.)
- Siemens Healthcare GmbH (Germany)
- Hologic, Inc. (U.S.)
- Dynatronics Corporation (U.S.)
- Ito Co., Ltd (Japan)
SKU-